The MRG-002 drug is an alternative to MRG-001 specifically developed for treating skin related wound injuries. MRG-002 is a fixed-dose drug combination consisting of plerixafor and a novel compound named FKVP.
FKVP is a non-immunosuppressive analog to FK506 or better known as tacrolimus. FKVP does not inhibit calcineurin. Instead, it activates the bone morphogenic pathway (BMP) signaling in human cells. This pathway is known for stimulating growth and differentiation. FKVP is able to significantly reduce wound healing time to a similar degree as MRG-001 without the potential side-effects of calcineurin inhibition and subsequent immunosuppression.
